Stephen Dilly, M.D., Ph.D
CEO and President
Member, Board of Directors

Stephen Dilly joined APT as its CEO and president in April 2006. He has over 20 years of experience in the biotech space and is well-prepared to lead APT into its next stage of growth. Stephen previously served as the Senior Vice President of Development and Chief Medical Officer for Chiron BioPharma. He also held executive positions for Genentech and SmithKline Beecham. Throughout his career, Stephen has been closely associated with the successful development and launch of a wide array of important drugs, including: Kytril, Paxil CR, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. He currently serves on the board of directors for Avigen, a biopharmaceutical company developing innovative therapies for neurological conditions. Stephen earned an M.D. from the University of London in 1982 and earned a Ph.D in cardiac physiology from the University of London in 1988.

Albert Cha, M.D., Ph.D
Member, Board of Directors

Albert Cha lends his expertise in neuroscience and medical devices to APT. Albert is currently a partner of Vivo Ventures. He joined the firm in 2000 and became a partner in 2000. Albert is an accomplished scientist who has published several research articles on molecular biophysics in journals such as Nature and Neuron. In addition to his academic qualifications, Albert worked for Oracle Corporation in pharmaceutical consulting. He earned a Bachelor’s Degree from Stanford University and an M.D. with honors and a Ph.D in neuroscience from the University of California at Los Angeles.

William Harrington, M.D.
Member, Board of Directors

Dr. Harrington brings a long clinical and financial experience in medical technology to APT. Bill is a partner at Three Arch Partners, where he has been since 1999, focusing exclusively on investments in medical devices, biotechnology and health care services. Dr. Harrington is a fellowship-trained interventional radiologist and practiced for 8 years before leaving clinical medicine for venture capital in 1998. He has a broad experience with minimally invasive surgical procedure, new technology introduction and clinical trials. Bill currently sits on the boards of a number of health care companies, including Reliant Technologies, Satiety, Cameron Health, Spinal Motion, Baxano, Voyage Medical, NeuroVista and Benvenue. Bill earned his M.D. from Harvard Medical School and his MBA from the University of California at Berkeley. He is a CFA charterholder.

David E. Kroin
Member, Board of Directors

Mr. Kroin is a co-founder of Great Point Partners, LLC. Mr. Kroin is a co-portfolio manager who also covers the biotechnology sector for the Biomedical Value Fund and is a member of the Private Equity Investment Committee. Previously, Mr. Kroin was a Partner in J.H. Whitney & Co. funds and since 1998, he was a senior member of the health care group at J.H. Whitney & Co. While at J.H. Whitney & Co., he was a Board Member of US Bioservices Corp. (acquired by AmeriSource), Icon International Inc. (acquired by Omnicom) and several other companies. Mr. Kroin previously worked in the corporate finance and mergers and acquisitions group at Merrill Lynch & Co. Mr. Kroin graduated from the University of Michigan with a B.S. in actuarial mathematics.

Camille Samuels
Member, Board of Directors

Camille Samuels specializes in biotechnology investing at Versant. Camille joined Versant in early 2000, shortly after its formation.

Prior to Versant, Camille was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Camille worked in business development/strategic planning at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting.

Camille currently serves as a board member of the following companies: Achaogen, APT Pharmaceuticals, JwalaCo, Kythera Biopharmaceuticals, and Novacea, a public company. Camille was previously a board member at NovaCardia (acquired by Merck) and ParAllele (acquired by Affymetrix). In addition, she served as a board observer at several companies, including Alexza (public), Fluidigm, Genomic Health (public) and Syrrx (sold).

Camille earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.

Fred M. Schwarzer
Member, Board of Directors

Mr. Schwarzer brings a wealth of business experience to APT. He has expertise in operations, fundraising, developing corporate partnerships and structuring venture capital investments

Mr. Schwarzer is currently a managing director for Charter Life Sciences. He has been chief executive officer, and then chairman, of two Charter portfolio biotech companies, Heska (HSKA) and Palingen. Mr. Schwarzer has also been the president and chief executive officer of Mingly Capital Corporation, which was focused on developing cross-border opportunities in life sciences and information technology. He was executive director of The Mingly Corporation Limited (listed on the Hong Kong Stock Exchange) and prior to that he was a senior vice president of C.M. Capital, a diversified asset management company. At the beginning of his professional career, Mr. Schwarzer was a lawyer working with technology companies and venture capitalists. In 1985, he was made a partner with Pillsbury, Madison & Sutro (now Pillsbury, Winthrop) and in 1988 he founded the firm of General Counsel Associates (now GCA Law Partners). Mr. Schwarzer received a B.A. from the University of Michigan and a J.D. from the University of California at Berkeley's Boalt Hall School of Law.

Paul Sekhri
Member, Board of Directors

Paul Sekhri is the President and CEO of Cerimon Pharmaceuticals. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. In 2002, Mr. Sekhri joined the Sprout Group where he was a Partner for healthcare technology investments. Prior to joining Sprout, Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.

Mr. Sekhri holds several other board member appointments including ARYx Therapeutics and the Cancer Research Institute. He is a member of the Advisory Board for The BioExec Institute, Inc., and an advisor to the Brookings Global Health Financing Initiative. Mr. Sekhri is a Venture Partner with MPM Capital, one of the largest Venture Capital firms devoted to the life sciences.

Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology.